Quantcast
Last updated on April 19, 2014 at 8:45 EDT

PharmaVentures Helps Secure Investor for Former MSD Research Site

January 19, 2012

OXFORD, England, January 19, 2012 /PRNewswire/ –

PharmaVentures announced today that it was delighted to act as transaction advisor to
MSD (operating in the US and Canada as Merck & Co) to secure its deal with BioCity
Scotland, a new joint venture between BioCity Nottingham and Roslin BioCentre, for the
former MSD research facility in Newhouse, Lanarkshire.

The deal follows exceptional collaborative working between MSD, the Scottish Life
Sciences community and the Scottish Government.

The transfer of this research facility from MSD to BioCity Scotland unlocks over
130,000 sq ft of purpose-built laboratories and offices on the 23 acre site capable of
supporting drug discovery and development for growing bioscience, pharmaceutical, med-tech
and healthcare companies.

Fintan Walton, Chief Executive of PharmaVentures, said: “PharmaVentures is delighted
to have worked with MSD in finding a new investor like BioCity Scotland to turn the former
MSD research facility into an incubator for growing innovative enterprises. This is a
fantastic outcome for the site and for the UK Life Science industry as a whole, creating
new job opportunities from start-up companies and providing the infrastructure to support
expansion of existing businesses.”

Note to Editors

If you wish to write an article, please contact us for any further information you
require.

About PharmaVentures:

PharmaVentures (http://www.pharmaventures.com) is an international healthcare
advisory group providing leadership in all aspects of deals and alliances, from strategy
formulations to implementation. The company occupies a special position in the global
marketplace because of their track record of successful outcomes, resulting from their
unique insight into the world of deal making, their internationally recognised analytical
and valuation capabilities, their own proprietary deal making database PharmaDeals(R)
(http://www.pharmadeals.net), containing over 42,000 deal records, and their extensive
business relationship network and our outstanding success in M&A transactions.

Over the years PharmaVentures has built considerable experience in the M&A field
including the divestment of manufacturing and R&D businesses most of which have led to
both the protection and the creation of jobs.

Their services cover:

        - Valuation (for licensing, acquisitions, divestments, fund raising & expert
          testimonies)
        - Licensing (in and out-licensing)
        - M&A (companies & assets)
        - Strategy (commercialisation, deal strategy, due diligence, market entry)
        - Expert Testimony (patent infringement, deal disagreements, taxation,
          determining damages)

Now in its 20th year, PharmaVentures is based in Oxford, UK, and employs over 30
people.

PharmaDeals(R) and PharmaVentures(R) are registered Trade Marks of PharmaVentures Ltd.

        For further information, contact:

        Dr Fintan Walton, Chief Executive, PharmaVentures
        +44(0)1865-332-700
        fintan.walton@pharmaventures.com

SOURCE PharmaVentures


Source: PR Newswire